Who should consider triSure NIPT test?
The triSure NIPT test is unique NIPT test integrating mother’s carrier screening in one blood draw.
Patients
Prenatal screening for pregnant women
- Especially from week 09 of pregnancy onward.
- Pregnant women who want comprehensive screening for their children.
Couples preparing for a healthy pregnancy
Parents are preparing for IVF
Advanced paternal age
The older the father, the higher the likelihood of de novo mutations in the offspring. Specifically, the number of mutations in offspring increases by approximately 3–4% for each additional year of paternal age (1,2).
Abnormal ultrasound findings
Prospective validation at Gene Solutions demonstrated that in pregnancies with abnormal ultrasound findings, the noninvasive prenatal test for single-gene conditions detected monogenic disorders in approximately 13.98% of cases (3).
Ultrasound abnormalities inclusing:
- Increased nuchal translucency (NT ≥ 3.5 mm)
- Hydrops fetalis
- Cystic hygroma
- Skeletal dysplasia
- Complex congenital heart defects (e.g., AVSD, tetralogy of Fallot)
- Brain and liver anomalies
Family history of hereditary conditions
Individuals with a family history of hereditary conditions may benefit from noninvasive prenatal testing for single- gene disorders (4).
Want to know
ACMG: “All pregnant patients and those planning a pregnancy should be offered Tier 3 carrier screening for autosomal recessive (carrier frequency ≥1/200) and X-linked conditions”.
Advanced paternal age
The older the father, the higher the likelihood of de novo mutations in the offspring. Specifically, the number of mutations in offspring increases by approximately 3–4% for each additional year of paternal age (1,2).
Abnormal ultrasound findings
Prospective validation at Gene Solutions demonstrated that in pregnancies with abnormal ultrasound findings, the noninvasive prenatal test for single-gene conditions detected monogenic disorders in approximately 13.98% of cases (3).
Ultrasound abnormalities inclusing:
- Increased nuchal translucency (NT ≥ 3.5 mm)
- Hydrops fetalis
- Cystic hygroma
- Skeletal dysplasia
- Complex congenital heart defects (e.g., AVSD, tetralogy of Fallot)
- Brain and liver anomalies
Family history of hereditary conditions
Individuals with a family history of hereditary conditions may benefit from noninvasive prenatal testing for single- gene disorders (4).
Want to know
- (1) Taylor et al. Paternal-Age-Related de Novo Mutations and Risk for Five Disorders. Nat Commun. 2019.
- (2) Kong et al. Rate of de Novo Mutations and the Importance of Father’s Age to Disease Risk. Nature. 2012.
- (3) Tran et al. De Novo Variants of Dominant Monogenic Disorders in Vietnam Detected by a Noninvasive Prenatal Test: A Case Series. Per. Med. 2023.
- (4) Mohan et al. Clinical Experience with Non‐invasive Prenatal Screening for Single‐gene Disorders. Ultrasound in Obstet & Gyne. 2022.
Compared to Biochemical Screening
What is the difference between triSure NIPT and Biochemical Screening?
There is a 25-fold reduction in unnecessary amniocentesis
Only 3 of every 100 positive cases are abnormal, with the remaining 97 cases being amniocentesis.
Biochemical test
There are 97 abnormal cases for every 100 positive cases, minimizing inappropriate amniocentesis.
triSure NIPT
- Published in the Vietnam Medical Journal “Determining the positive predictive value of the noninvasive prenatal test NIPT in medical practice.”
Missed cases are reduced by 15 times (false negatives)
85% detection rate
(for every 100 cases, 15 cases are missed)
Biochemical test
99% detection rate
(for every 100 cases, less than 1 case is missed)
triSure NIPT
- (Grace et al. Obstet Gynecol Surv, 2016 August, 71(8): 477-487)
